Retroperitoneal Lymph Node Dissection in Testicular Cancer

Niels Erik B. Jacobsen, Richard S. Foster, John P. Donohue

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

With long-term survival in excess of 90% across all stages, testicular cancer has come to represent the model for successful multidisciplinary cancer care. Retroperitoneal lymph node dissection (RPLND) remains an integral component of testis cancer management strategies for both early- and advanced-stage disease. Commensurate with improvements made in clinical staging and in our understanding of the natural history of testis cancer, lymphatic spread, and neuroanatomy, considerable modifications in the technique and template of RPLND have taken place. The morbidity of primary RPLND and postchemotherapy RPLND is low when performed by experienced surgeons. This article reviews the evolution, role, and technique of RPLND in contemporary practice.

Original languageEnglish (US)
Pages (from-to)199-220
Number of pages22
JournalSurgical Oncology Clinics of North America
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Retroperitoneal Lymph Node Dissection in Testicular Cancer'. Together they form a unique fingerprint.

  • Cite this